[Modern Fixed Combinations in the Correction of Arterial Hypertension and Dyslipidemia].

IF 0.5 4区医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Kardiologiya Pub Date : 2024-05-31 DOI:10.18087/cardio.2024.5.n2656

Z M Galeeva, A S Galyavich, L V Baleeva, A A Sabirzyanova, M V Kuznetsov

引用次数: 0

Abstract

Based on a clinical case report, the article shows the individual selection of effective therapy for a patient with arterial hypertension and dyslipidemia. Taking into account the risk factors for cardiovascular diseases, Equamer® was selected as a fixed combination of amlodipine + lisinopril + rosuvastatin capsules 10 mg+20 mg+10 mg (Gedeon Richter Plc, Budapest, Hungary). In the patient with hypertension, ischemic heart disease was verified, and stenting of the anterior descending artery was performed. According to the clinical guidelines, when arterial hypertension is associated with ischemic heart disease, the drug therapy of choice should be a combination of dihydropyridine slow calcium channel blockers with an angiotensin-converting enzyme inhibitor. The fixed triple combination of amlodipine, lisinopril, and rosuvastatin is one of the most appropriate in this clinical situation; this combination targets the two major risk factors for cardiovascular diseases, arterial hypertension and dyslipidemia.

查看原文本刊更多论文

[纠正动脉高血压和血脂异常的现代固定组合疗法]。

文章以临床病例报告为基础，介绍了如何为动脉高血压和血脂异常患者单独选择有效疗法。考虑到心血管疾病的风险因素，Equamer® 被选为氨氯地平+利辛普利+洛伐他汀胶囊 10 毫克+20 毫克+10 毫克（Gedeon Richter Plc，匈牙利布达佩斯）的固定组合。高血压患者经核实患有缺血性心脏病，并进行了前降支动脉支架植入术。根据临床指南，当动脉性高血压伴有缺血性心脏病时，药物治疗应选择二氢吡啶类慢钙通道阻滞剂与血管紧张素转换酶抑制剂的组合。在这种临床情况下，氨氯地平、利辛普利和罗伐他汀的固定三联疗法是最合适的疗法之一；这种疗法针对心血管疾病的两大危险因素--动脉高血压和血脂异常。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Kardiologiya 医学-心血管系统

CiteScore

1.70

自引率

20.00%

发文量

审稿时长

3-8 weeks

期刊介绍： “Kardiologiya” (Cardiology) is a monthly scientific, peer-reviewed journal committed to both basic cardiovascular medicine and practical aspects of cardiology. As the leader in its field, “Kardiologiya” provides original coverage of recent progress in cardiovascular medicine. We publish state-of-the-art articles integrating clinical and research activities in the fields of basic cardiovascular science and clinical cardiology, with a focus on emerging issues in cardiovascular disease. Our target audience spans a diversity of health care professionals and medical researchers working in cardiovascular medicine and related fields. The principal language of the Journal is Russian, an additional language – English (title, authors’ information, abstract, keywords). “Kardiologiya” is a peer-reviewed scientific journal. All articles are reviewed by scientists, who gained high international prestige in cardiovascular science and clinical cardiology. The Journal is currently cited and indexed in major Abstracting & Indexing databases: Web of Science, Medline and Scopus. The Journal''s primary objectives Contribute to raising the professional level of medical researchers, physicians and academic teachers. Present the results of current research and clinical observations, explore the effectiveness of drug and non-drug treatments of heart disease, inform about new diagnostic techniques; discuss current trends and new advancements in clinical cardiology, contribute to continuing medical education, inform readers about results of Russian and international scientific forums; Further improve the general quality of reviewing and editing of manuscripts submitted for publication; Provide the widest possible dissemination of the published articles, among the global scientific community; Extend distribution and indexing of scientific publications in major Abstracting & Indexing databases.